Canaccord downgraded Inari Medical (NARI) to Hold from Buy with a price target of $80, up from $74, after Stryker (SYK) entered into a definitive agreement to acquire Inari in cash for $80 per share. Following the announcement, Canaccord does not expect other large strategics to push the bid on Inari.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NARI: